CADTH is committed to supporting Canada’s health care decision-makers through this challenging and uncertain time.
For evidence, tools, and resources related to COVID-19, visit our COVID-19 Evidence Portal.
| Project Number | PC0042-000 |
|---|---|
| Brand Name | Yervoy |
| Generic Name | Ipilimumab |
| Strength | 5mg/mL |
| Tumour Type | Skin and Melanoma |
| Indication | First Line Advanced Melanoma |
| Funding Request | For the first-line treatment of adult patients with advanced (unresectable or metastatic) melanoma |
| Review Status | Complete |
| Pre Noc Submission | Yes |
| NOC Date | September 10, 2014 |
| Manufacturer | Bristol-Myers Squibb Canada |
| Sponsor | Bristol-Myers Squibb Canada |
| Submission Date | August 15, 2014 |
| Submission Deemed Complete | August 22, 2014 |
| Submission Type | Initial |
| Prioritization Requested | Not Requested |
| Stakeholder Input Deadline ‡ | August 29, 2014 |
| Check-point meeting | October 6, 2014 |
| pERC Meeting | November 20, 2014 |
| Initial Recommendation Issued | December 4, 2014 |
| Feedback Deadline ‡ | December 18, 2014 |
| Final Recommendation Issued | December 22, 2014 |
| Notification to Implement Issued | January 14, 2015 |
| Therapeutic Area | First Line Advanced Melanoma |
| Recommendation Type | Reimburse with clinical criteria and/or conditions |
‡ Patient Advocacy Groups (or individual patients and caregivers when there is no patient group) and Clinicians who are registered with pCODR are eligible to provide Input and Feedback. Deadlines for Input and Feedback are by the end of the pCODR business day (5P.M. Eastern Time) of the date noted.
